UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SA 11.4 Duration of endocrine therapy in early breast cancer

Breast (Edinburgh), 2023-04, Vol.68, p.S12-S12

Huober, J.

2023

Volltextzugriff (PDF)

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Annals of oncology, 2017-08, Vol.28 (8), p.1700-1712

2017

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Annals of oncology, 2022-11, Vol.33 (11), p.1149-1158

2022

Volltextzugriff (PDF)

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Annals of oncology, 2022-04, Vol.33 (4), p.384-394

2022

Volltextzugriff (PDF)

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Annals of oncology, 2013-11, Vol.24 (11), p.2786-2793

2013

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Annals of oncology, 2015-01, Vol.26 (1), p.113-119

2015

Volltextzugriff (PDF)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Annals of oncology, 2020-09, Vol.31 (9), p.1216-1222

2020

Volltextzugriff (PDF)

Moderne Therapie beim metastasierten triple-negativen Mammakarzinom

Best practice onkologie, 2020-10, Vol.15 (10), p.416-424

2020

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Volltextzugriff (PDF)

Moderne Therapie beim frühen Mammakarzinom

Best practice onkologie, 2020-06, Vol.15 (6), p.242-250

2020

Volltextzugriff (PDF)

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Volltextzugriff (PDF)

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Annals of oncology, 2024-08, Vol.35 (8), p.718-727

2024

Volltextzugriff (PDF)

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

Annals of oncology, 2012-11, Vol.23 (11), p.2843-2851

2012

Volltextzugriff (PDF)

Innovationen in der medikamentösen Therapie des Mammakarzinoms

Gynäkologe (Berlin), 2014-12, Vol.47 (12), p.920-924

2014

Volltextzugriff (PDF)

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Annals of oncology, 2021-08, Vol.32 (8), p.1061-1062

2021

Volltextzugriff (PDF)

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

Breast (Edinburgh), 2012-02, Vol.21 (1), p.27-33

2012

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2014-08, Vol.25 (8), p.1551-1557

2014

Volltextzugriff (PDF)

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients

Annals of oncology, 2017-08, Vol.28 (8), p.1803-1810

2017

Volltextzugriff (PDF)

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Breast cancer research and treatment, 2014-01, Vol.143 (1), p.159-169

2014

Volltextzugriff (PDF)

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

Annals of oncology, 2012-09, Vol.23 (9), p.2271-2277

2012

Volltextzugriff (PDF)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

ESMO open, 2021-12, Vol.6 (6), p.100299-100299, Article 100299

2021

Volltextzugriff (PDF)

1 – 25 von 442

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(390)
Mit Volltextzugriff
(380)

Publikationsform

Sprache

Englisch
(326)
Deutsch
(122)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(91)
Oncology
(91)
Science & Technology
(91)
Humans
(86)
Female
(79)
Middle Aged
(54)
Adult
(47)
Breast Cancer
(46)
Aged
(42)
Breast Neoplasms - Drug Therapy
(39)
Tumors
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(34)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Breast Neoplasms - Pathology
(32)
Antineoplastic Agents
(25)
Disease-Free Survival
(25)
Pharmacology. Drug Treatments
(25)
Neoadjuvant Therapy
(24)
Treatment Outcome
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(100)
Cancer Research
(69)
Journal Of Clinical Oncology
(47)
Geburtshilfe Und Frauenheilkunde
(20)
European Journal Of Cancer
(16)
Senologie
(12)
Gynäkologe
(11)
Gynäkologie
(11)
Breast
(8)
International Journal Of Gynecological Cancer
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

SA 11.4 Duration of endocrine therapy in early breast cancer

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Moderne Therapie beim metastasierten triple-negativen Mammakarzinom

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Moderne Therapie beim frühen Mammakarzinom

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

Innovationen in der medikamentösen Therapie des Mammakarzinoms

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

Suchergebnisse filtern